634 results on '"Merli, Pietro"'
Search Results
2. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
3. Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study
4. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
5. A Day 14 Endpoint for Acute GVHD Clinical Trials
6. TCRαβ/CD19 cell–depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis
7. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
8. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
9. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
10. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL
11. Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient
12. Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients
13. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
14. Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH
15. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
16. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
17. Autologous CD19‐Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis.
18. TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
19. Clinical, Immunological, and Molecular Variability of RAG Deficiency: A Retrospective Analysis of 22 RAG Patients
20. P101 Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus
21. GATA2 and marrow failure
22. HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia
23. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III
24. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
25. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis
26. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
27. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
28. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
29. PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation
30. The utility of biomarkers in acute GVHD prognostication
31. Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy
32. Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers
33. Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia
34. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as predictor of mortality in children
35. Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies
36. Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion
37. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
38. Allogeneic, donor-derived, second-generation, CD19-CAR-T cell for the treatment of pediatric relapsed/refractory BCP-ALL
39. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
40. Data from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
41. Supplementary Data from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
42. Achievement of operational tolerance in a pediatric liver transplant recipient following successful hematopoietic stem cell transplantation from a different donor
43. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors
44. Neutralization of IFNγ improves the safety profile of CAR T-cells while maintaining unaffected efficacy against B-cell malignancies
45. TCRαβ/CD19 depleted hematopoietic stem cell transplantation from haploidentical donors: dissecting the GvL/GvHD conundrum
46. Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT
47. Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders
48. De Novo Late Acute Gvhd: Incidence, Outcomes, and Impact of Biomarkers Compared to Classic Acute Gvhd
49. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients
50. Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.